Immunologic Research

, Volume 32, Issue 1–3, pp 155–168 | Cite as

CD25+CD4+ regulatory T-cells in cancer



Regulatory T-cells (Treg) protect the host from autoimmune disease by suppressing self-reactive immune cells. As such, Treg may also block antitumor immune responses. Recent observations by us and others showed that the prevalence of Treg is increased in cancer patients, particularly in the tumor environment. Our studies in a mouse pancreas cancer model suggest that the tumor actively promotes the accural of Treg through several mechanisms involving activation of naturally occurring Treg as well as conversion of non-Treg into Treg. Our studies focus on further defining these mechanisms with the ultimate goal of designing strategies that block Treg-mediated suppression in cancer patients.

Key Words

Regulatory T-cells Suppression Cancer Anticancer immunity Depletion Transforming growth factor-β Foxp3 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151–1164.PubMedGoogle Scholar
  2. 2.
    Takahashi T, Kuniyasu Y, Toda M, et al: Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998;10:1969–1980.PubMedCrossRefGoogle Scholar
  3. 3.
    Shevach EM, McHugh RS, Thornton AM, Piccirillo C, Natarajan K, Margulies DH: Control of autoimmunity by regulatory T cells. Adv Exp Med Biol 2001;490;21–32.PubMedGoogle Scholar
  4. 4.
    Kojima A, Tanaka-Kojima Y, Sakakura T, Nishizuka Y: Spontaneous development of autoimmune thyroiditis in neonatally thymectomized mice. Lab Invest 1976;34: 550–557.PubMedGoogle Scholar
  5. 5.
    Stumbles PA, Penhale WJ: IDDM in rats in duced by thymectomy and irradiation. Diabetes 1993;42:571–578.PubMedCrossRefGoogle Scholar
  6. 6.
    Kontani K, Taguchi O, Takahashi T: Involvement of the H+/K(+)-ATPase alpha subunit as a major antigenic protein in autoimmune gastritis induced by neonatal thymectomy in mice. Clin Exp Immunol 1992;89:63–67.PubMedCrossRefGoogle Scholar
  7. 7.
    Kojima A, Sakakura T, Tanaka Y, Nishizuka Y: Sterility in neonatally thymectomized female mice: its nature and prevention by the injection of spleen cells. Biol Reprod 1973;8:358–361.PubMedGoogle Scholar
  8. 8.
    Green EA, Choi Y, Flavell, RA: Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity 2002;16:183–191.PubMedCrossRefGoogle Scholar
  9. 9.
    Green EA, Gorelik L, McGregor CM, Tran EH, Flavell RA: CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proc Natl Acad Sci USA 2003;100:10,878–10,883.Google Scholar
  10. 10.
    Malmstrom V, Shipton D, Singh B, et al: CD134L expression on dendritic cells in the mesenteric lymph nodes drives colitis in T cell-restored SCID mice. J Immunol 2001;166:6972–6981.PubMedGoogle Scholar
  11. 11.
    Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057–1061.PubMedCrossRefGoogle Scholar
  12. 12.
    Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330–336.PubMedCrossRefGoogle Scholar
  13. 13.
    Thornton AM, Shevach EM: Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 2000;164:183–190.PubMedGoogle Scholar
  14. 14.
    Walker LS, Chodos A, Eggena M, Dooms H, Abbas AK: Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J Exp Med 2003;198: 249–258.PubMedCrossRefGoogle Scholar
  15. 15.
    Yanagiwa S, Gray JD, Hashimoto S, Horwitz DA: A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory t cells from human peripheral blood. J Immunol 2001;166:7282–7289.Google Scholar
  16. 16.
    Gavin MA, Clarke SR, Negrou E, Gallegos A, Rudensky A: Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo. Nat Immunol 2002;3:33–41.PubMedCrossRefGoogle Scholar
  17. 17.
    Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S: Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002;3:135–142.PubMedCrossRefGoogle Scholar
  18. 18.
    Stephens LA, Mottet C, Mason D, Powrie F: Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol 2001;31:1247–1254.PubMedCrossRefGoogle Scholar
  19. 19.
    Piccirillo CA, Shevach EM: Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001;167:1137–1140.PubMedGoogle Scholar
  20. 20.
    Azuma T, Takahashi T, Kunisato A, Kitamura T, Hirai H: Human CD4+ CD25+ regulatory T cells suppress NKT cell functions. Cancer Res 2003;63:4516–4520.PubMedGoogle Scholar
  21. 21.
    Khattri R, Cox T, Yasayko SA, Ramsdell F: An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003;4:337–342.PubMedCrossRefGoogle Scholar
  22. 22.
    Bruder D, Probst-Kepper M, Westendorf AM, et al: Neuropilin-1: a surface marker of regulatory T cells. Eur J Immunol 2004;34:623–630.PubMedCrossRefGoogle Scholar
  23. 23.
    Mizobuchi T, Yasufuku K, Zheng Y, et al: Differential expression of Smad7 transcripts identifies the CD4(+) CD45RC(high) regulatory T cells that mediate type V collagen-induced tolerance to lung allografts. J Immunol 2003;171:1140–1147.PubMedGoogle Scholar
  24. 24.
    Shankaran V, Ikeda H, Bruce AT, et al: IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410: 1107–1111.PubMedCrossRefGoogle Scholar
  25. 25.
    Smyth MJ, Thia KY, Street SE, et al: Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000;191:661–668.PubMedCrossRefGoogle Scholar
  26. 26.
    Street SE, Hayakawa Y, Zhan Y, et al: Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and {gamma} {delta} T cells. J Exp Med 2004;199:879–884.PubMedCrossRefGoogle Scholar
  27. 27.
    Pardoll D: Does the immune system see tumors as foreign or self. Annu Rev Immunol 2003;21:807–839.PubMedCrossRefGoogle Scholar
  28. 28.
    Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991–998.PubMedCrossRefGoogle Scholar
  29. 29.
    Woo EY, Yeh H, Chu CS, et al: Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cells proliferation. J Immunol 2002; 168:4272–4276.PubMedGoogle Scholar
  30. 30.
    Woo EY, Chu CS, Goletz TJ, et al: Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766–4772.PubMedGoogle Scholar
  31. 31.
    Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B: Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9:606–612.PubMedGoogle Scholar
  32. 32.
    Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A: CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003; 98:1089–1099.PubMedCrossRefGoogle Scholar
  33. 33.
    Awwad M, North RJ: Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res 1989;49:1649–1654.PubMedGoogle Scholar
  34. 34.
    Awwad M, North RJ: Radiosensitive barrier to T-cell-mediated adoptive immunotherapy of established tumors. Cancer Res 1990;50:2228–2233.PubMedGoogle Scholar
  35. 35.
    North RJ, Dye ES: Ly 1+2- suppressor T cells down-regulate the generation of Ly 1–2+ effector T cells during progressive growth of the P815 mastocytoma. Immunology 1985;54:47–56.PubMedGoogle Scholar
  36. 36.
    Rakhmilevich AL, North RJ, Dye ES: Presence of CD4+ T suppressor cells in mice rendered unresponsive to tumor antigens by intravenous injection of irradiated tumor cells. Int J Cancer 1993;55:338–343.PubMedCrossRefGoogle Scholar
  37. 37.
    Awwad M, North RJ: Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody: a consequence of removing L3T4+ Lyt-2+T cell-mediated immunity. J Exp Med 1988; 168:2193–2206.PubMedCrossRefGoogle Scholar
  38. 38.
    North RJ, Awwad M: Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases noncycling CD8+ T cells to cause regression of an advanced lymphoma Immunology 1990;71:90–95.PubMedGoogle Scholar
  39. 39.
    Shimizu J, Yamazaki S, Sakaguchi S: Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999;163:5211–5218.PubMedGoogle Scholar
  40. 40.
    Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E: Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999;59:3128–3133.PubMedGoogle Scholar
  41. 41.
    Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al: Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001:194:823–832.PubMedCrossRefGoogle Scholar
  42. 42.
    Rosenberg SA: Development of effective immunotherapy for the treatment of patients with cancer. J Am Coll Surg 2004;198:685–696.PubMedCrossRefGoogle Scholar
  43. 43.
    North RJ, Bursuker I: Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2-suppressor T cells down-regulate the generation of Ly-1–2+ effector T cells. J Exp Med 1984;159:1295–1311.PubMedCrossRefGoogle Scholar
  44. 44.
    Liyanage UK, Moore TT, Joo, GH, et al: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756–2761.PubMedGoogle Scholar
  45. 45.
    Viguier M, Lemaitre F, Verola O, et al: Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173:1444–1453.PubMedGoogle Scholar
  46. 46.
    Chen W, Jin W, Hardegen N, et al: Conversion of peripheral CD4+CD25-naïve T cells to CD4+CD25+regulatory T cells by TGFb induction of transcription factor Foxp3. J Exp Med 2003;198:1875–1886.PubMedCrossRefGoogle Scholar
  47. 47.
    von Bernstorff W, Voss M, Freichel S, et al: Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 2001;7:925s-932s.Google Scholar
  48. 48.
    Jonuleit H, Schmitt E, Steinbrink K, Enk AH: Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol 2001;22:394–400.PubMedCrossRefGoogle Scholar
  49. 49.
    Lohr J, Knoechel B, Jiang S, Sharpe AH, Abbas AK: The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens. Nat Immunol 2003;4:664–669.PubMedCrossRefGoogle Scholar
  50. 50.
    Yamazaki S, Iyoda T, Tarbell K, et al: Direct expansion of functional CD25+CD4+ regulatory T cells by antigen-processing dendritic cells. J exp Med 2003;198:235–247.PubMedCrossRefGoogle Scholar
  51. 51.
    Blattman JN, Greenberg PD: Cancer immunotherapy: a treatment for the masses. Science 2004;305:200–205.PubMedCrossRefGoogle Scholar
  52. 52.
    Nishikawa H, Kato T, Tanida K, et al: CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc Natl Acad Sci USA 2003;100:10,902–10,906.CrossRefGoogle Scholar
  53. 53.
    Wang HY, Lee DA, Peng G, et al: Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 2004;20:107–118.PubMedCrossRefGoogle Scholar
  54. 54.
    Wiethe C, Dittmar K, Doan T, Lindennaier W, Tindel R: Provision of 4-1 BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen. J Immunol 2003;170:2912–2922.PubMedGoogle Scholar
  55. 55.
    Zheng G, Wang B, Chen A: The 4—1BB costimulation augments the proliferation of CD4+CD25+ regulatory T cells. J Immunol 2004;173:2428–2434.PubMedGoogle Scholar
  56. 56.
    Awwad M, North RJ: Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour: evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunology 1988;65:87–92.PubMedGoogle Scholar
  57. 57.
    Dudley ME, Wunderlich JR, Robbins PF, et al: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850–854.PubMedCrossRefGoogle Scholar
  58. 58.
    Dudley ME, Wunderlich JR, Yang JC, et al: A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 2002;25:243–251.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 2005

Authors and Affiliations

  1. 1.Department of Surgery and Alvin J. Siteman Cancer CenterWashington University School of MedicineSt. Louis

Personalised recommendations